Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
NEW YORK, May 15, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Lion Biotechnologies, Inc. ("Lion Biotechnologies") (NASDAQ:LBIO) securities between November 14, 2013 and April 10, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/lion-biotechnologies-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) through its former CEO Manish Singh, Lion was engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting the Company to potential investors that purported to be independent from the company when, in truth, they were paid promotions; (2) Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion on investment websites, as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) Singh actively participated in the promotional work for the Company and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Lion Biotechnologies you have until June 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/lion-biotechnologies-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
